Brought to you by 
Hyundai Pharm gets South Korean rights to Aslan's cholangiocarcinoma project
16 Mar 2020
Executive Summary
Aslan Pharmaceuticals Pte. Ltd. and Hyundai Pharm Co. Ltd. will work together on the development and commercialization in South Korea of Aslan's varlitinib (ASLAN001) for cholangiocarcinoma.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com